Fig. 8. Effects of Xrx1 loss of function on genes regulating anterior neurogenesis. (A-C) Phenotypes of stage 41 embryos injected with MoXrx1 (A), MoXrx1 and Xrx1 (B), and control morpholino oligo (C). (F,J,K,M,N,Q) Embryos injected with MoXrx1 in both dorsoanimal blastomeres at the eight-cell stage and analyzed at stage 14 (F,K,M,N,Q) and stage 18 (J). (D,G,H,L,P) Control uninjected embryos analyzed at stage 14 (D,G,L,P) and stage 18 (H). (E,I) Embryos bilaterally injected with Xrx1-EnR analyzed at stage 14 (E) and stage 18 (I). (O) Stage 14 embryo treated with HUA. (R,S,V) Stage 14 embryos bilaterally injected with Xhairy2 (R), MoXrx1 and Xhairy2 (S), and MoXrx1 and XBF-1 (V). (T,U) Dorsal (T) and frontal (U) views of a stage 14 embryo injected with XBF-1. Red staining represents co-injected lacZ. Black brackets indicate the size of the anterior expression domain in the uninjected embryo (P); white brackets indicate the size of the corresponding domain in the injected embryo (Q). Arrows in D,E,F,S,V indicate the anterior boundaries of X-ngnr-1 expression; the arrow in T indicates X-ngnr-1 ectopic expression. Black arrowheads in I,J indicate the continuous anterior extension of X-ngnr-1 expression. White arrowheads in U and R indicate the repressed anterior expression domain of X-ngnr-1.